| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_594df243712f7d149bfa7cb6dc55cf0d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4858
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-13 |
| filingDate |
1997-04-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d5fed9801ba8a07ba79f1b09a4c274d2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4e578a2fa1b80380a445e50b71a966f8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7057766a24b8b3df08de4425e26019f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8edae6e0fae85de41f7836f9e7adb0e0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9448e170dd54850ee34ba2fc60c2004 |
| publicationDate |
1998-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
BG-101443-A |
| titleOfInvention |
CYCLOSPORINE COMPOSITIONS FOR ORAL ADMINISTRATION |
| abstract |
The compositions find application in immunosuppressive therapy. They are highly bioavailable and can be administered in the form of hard capsules or nanoparticles. Cyclosporin is delivered to the compositions by an orally acceptable excipient comprising at least one alkanolic solvent of 2 to 3 carbon atoms in combination with at least one non-ionic surfactant. The compositions may also include at least one co-solvent, for example fatty acids and diols. |
| priorityDate |
1995-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |